{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:45:07Z","timestamp":1792903507273,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:27:12Z","timestamp":1769833632000},"page":"772-776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7650","authenticated-orcid":false,"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan L.","family":"Raizenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.01.006_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.01.006_b0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.006_b0015","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of Decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.006_b0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamaoncol.2020.6086","article-title":"Regional adoption of commercial gene expression testing for prostate cancer","volume":"7","author":"Leapman","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.01.006_b0025","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.01.006_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy Gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.01.006_b0035","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.euo.2024.06.007","article-title":"Use of Decipher prostate biopsy test in patients with favorable-risk disease undergoing conservative management or radical prostatectomy in the Surveillance, Epidemiology, and End Results registry","volume":"7","author":"Zhu","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.006_b0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.euo.2025.06.005","article-title":"The natural history of confirmed grade group 1 prostate cancer managed with active surveillance in the modern era","volume":"8","author":"Shee","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.006_b0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JU.0000000000000175","article-title":"Correlation of a commercial genomic risk classifier with histological patterns in prostate cancer","volume":"202","author":"Greenland","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.01.006_b0050","doi-asserted-by":"crossref","unstructured":"Shee K, Cowan JE, Ding CKC, et al. Gleason grade group 3 represents a spectrum of disease: results from a large institutional cohort. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2025.04.027.","DOI":"10.1016\/j.euf.2025.04.027"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:51Z","timestamp":1789577211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126000271"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}